Akero Therapeutics Ownership
| AKRO Stock | USD 32.10 0.07 0.22% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 69.2 M | Current Value 69.4 M | Avarage Shares Outstanding 37 M | Quarterly Volatility 15.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Akero |
Akero Stock Ownership Analysis
About 95.0% of the company shares are held by institutions such as insurance companies. The book value of Akero Therapeutics was presently reported as 10.61. The company has Price/Earnings To Growth (PEG) ratio of 0.93. Akero Therapeutics recorded a loss per share of 3.78. The entity had not issued any dividends in recent years. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Akero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 37 people. For more info on Akero Therapeutics please contact Andrew MD at 650 487 6488 or go to https://akerotx.com.Besides selling stocks to institutional investors, Akero Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Akero Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Akero Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Akero Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Akero Therapeutics Insider Trades History
About 5.0% of Akero Therapeutics are currently held by insiders. Unlike Akero Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Akero Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Akero Therapeutics' insider trades
Akero Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akero Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akero Therapeutics backward and forwards among themselves. Akero Therapeutics' institutional investor refers to the entity that pools money to purchase Akero Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-09-30 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Logos Global Management Lp | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Yiheng Capital Llc | 2024-06-30 | 1.4 M | Redmile Group, Llc | 2024-09-30 | 1.4 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.3 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 1.1 M | Hhg Plc | 2024-06-30 | 6.9 M | Blackrock Inc | 2024-06-30 | 5.6 M |
Akero Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akero Therapeutics Outstanding Bonds
Akero Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akero Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akero bonds can be classified according to their maturity, which is the date when Akero Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Akero Therapeutics Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Akero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akero Stock
| 0.72 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.85 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.8 | BHC | Bausch Health Companies | PairCorr |
Moving against Akero Stock
| 0.76 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.7 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.69 | HLN | Haleon plc | PairCorr |
| 0.68 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.66 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.